Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients

PURPOSE: ERBB2 exon 20 insertions (20ins) have been identified as oncogenic drivers in lung cancers. Lung cancer patients with 20ins benefit from afatinib. However, response heterogeneity was observed in patients harboring different 20ins subtypes. In this study, we interrogated clinical characteris...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Onco Targets Ther
Egile Nagusiak: Liu, Zhefeng, Wu, Lin, Cao, Jun, Yang, Zhe, Zhou, Chengzhi, Cao, Liming, Wu, Hao, Shen, Haibo, Jin, Meiling, Zhang, Yong, Mao, Xinru, Xiang, Jianxing, Ma, Ke, Li, Bing, Zhang, Tengfei, Hu, Yi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2018
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6205822/
https://ncbi.nlm.nih.gov/pubmed/30425522
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S173391
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak